• Arrowhead Pharmaceuticals will present clinical data at the American Heart Association Scientific Sessions in Chicago on Nov. 7, 2026.
• Oral presentations will feature first-in-human ARO-DIMER-PA data targeting PCSK9 and APOC3 in mixed hyperlipidemia.
• A pooled SHASTA-3 and SHASTA-4 analysis will address plozasiran’s triglyceride lowering and acute pancreatitis risk reduction in severe hypertriglyceridemia.
• Poster presentations will include three-year plozasiran efficacy and safety data in familial chylomicronemia syndrome from PALISADE and its open-label extension.
• Another poster will examine the impact of GLP-1 receptor agonist use on triglyceride reduction with plozasiran.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102145649) on November 02, 2026, and is solely responsible for the information contained therein.